Exploration of the association between SF3B4 and HMGB1 expression and the clinicopathological features and prognosis of gastric cancer

Table 3 Comparison of splicing factor 3b subunit 4 expression in tissues with different clinical data, n (%)

Item	Cases, n = 114	SF3B4 expression	t	P value
Gender			0.639	0.523
Male	71 (62.28)	1.53 ± 0.32
Female	43 (37.72)	1.49 ± 0.33
Age, years			0.293	0.769
≥ 60	47 (41.23)	1.53 ± 0.34
< 60	67 (58.77)	1.51 ± 0.37
Helicobacter pylori infection			0.000	1.000
Yes	101 (88.60)	1.50 ± 0.36
No	13 (11.40)	1.50 ± 0.33
Tumor location			0.268	0.789
Fundus	38 (33.33)	1.51 ± 0.34
Body	43 (37.72)	1.53 ± 0.33
Antrum	33 (28.95)	1.52 ± 0.35
CEA			0.444	0.657
Elevated	63 (55.26)	1.54 ± 0.38
Normal	51 (44.74)	1.51 ± 0.33
Pathological type			0.186	0.852
Adenocarcinoma	102 (89.47)	1.51 ± 0.35
Others	12 (10.53)	1.53 ± 0.37
Tumor differentiation			4.387	< 0.001
Moderate-high	68 (59.65)	1.35 ± 0.22
Poor	46 (40.35)	1.58 ± 0.34
Maximum tumor diameter, cm			7.620	< 0.001
< 5	71 (62.28)	1.26 ± 0.16
≥ 5	43 (37.72)	1.65 ± 0.38
Tumor invasion depth			6.980	< 0.001
T1-T2	35 (30.70)	1.23 ± 0.17
T3-T4	79 (69.30)	1.62 ± 0.31
Lymph node metastasis			10.197	< 0.001
Yes	84 (73.68)	1.04 ± 0.23
No	30 (26.32)	1.68 ± 0.43
cTNM stage			5.295	< 0.001
Stage I-II	34 (29.82)	1.25 ± 0.26
Stage III-IV	80 (70.18)	1.62 ± 0.37

SF3B4: Splicing factor 3b subunit 4; CEA: Carcinoembryonic antigen; cTNM: Clinical tumor-node-metastasis.